Opinion

Video

Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

Experts share high-level results from the investigation of cretostimogene grenadenorepvec, an investigational targeted immunotherapy delivered intravesically for the treatment of non–muscle-invasive bladder cancer (NMIBC).

Related Videos
1 expert in this video
1 expert in this video
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.